DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N

Emergent Product Development Gaithersbur, Gaithersburg MD

Investigators

Abstract

The primary objective of this project is to support the advanced development of candidate products which consist of a vaccine component in combination with a technology component (a dry formulation technology) to increase stability and minimize cold chain or preservative requirements for use in post-event settings following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens.